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Abstract
Objective:

Tourette’s syndrome is polygenic and highly heritable. Genome-wide association study (GWAS) approaches are
useful for interrogating the genetic architecture and determinants of Tourette’s syndrome and other tic
disorders. The authors conducted a GWAS meta-analysis and probed aggregated Tourette’s syndrome polygenic
risk to test whether Tourette’s and related tic disorders have an underlying shared genetic etiology and whether
Tourette’s polygenic risk scores correlate with worst-ever tic severity and may represent a potential predictor of
disease severity.

Methods:

GWAS meta-analysis, gene-based association, and genetic enrichment analyses were conducted in 4,819
Tourette’s syndrome case subjects and 9,488 control subjects. Replication of top loci was conducted in an
independent population-based sample (706 case subjects, 6,068 control subjects). Relationships between
Tourette’s polygenic risk scores (PRSs), other tic disorders, ascertainment, and tic severity were examined.

Results:

GWAS and gene-based analyses identified one genome-wide significant locus within FLT3 on chromosome 13,
rs2504235, although this association was not replicated in the population-based sample. Genetic variants
spanning evolutionarily conserved regions significantly explained 92.4% of Tourette’s syndrome heritability.
Tourette’s-associated genes were significantly preferentially expressed in dorsolateral prefrontal cortex.
Tourette’s PRS significantly predicted both Tourette’s syndrome and tic spectrum disorders status in the
population-based sample. Tourette’s PRS also significantly correlated with worst-ever tic severity and was higher
in case subjects with a family history of tics than in simplex case subjects.

Conclusions:

Modulation of gene expression through noncoding variants, particularly within cortico-striatal circuits, is
implicated as a fundamental mechanism in Tourette’s syndrome pathogenesis. At a genetic level, tic disorders
represent a continuous spectrum of disease, supporting the unification of Tourette’s syndrome and other tic
disorders in future diagnostic schemata. Tourette’s PRSs derived from sufficiently large samples may be useful in
the future for predicting conversion of transient tics to chronic tic disorders, as well as tic persistence and
lifetime tic severity.

Tourette’s syndrome is a complex neuropsychiatric disorder that occurs along a phenotypic spectrum that also
includes chronic (persistent) motor or vocal tic disorder (chronic tics) and transient (provisional) tic disorder (1).
Although Tourette’s syndrome is highly heritable (2), variants in known Tourette’s risk genes
(e.g., CNTN6, NRXN1, SLITRK1, HDC, and CELSR3) account for less than 2% of affected individuals (3–6).
Tourette’s syndrome is highly polygenic, with a demonstrated role for multiple common genetic variants of
small effect distributed widely across the genome (7). Thus, genome-wide association studies (GWASs) (8) will
be of benefit in further elucidating the underlying genetic etiology of the disorder.
To date, only one Tourette’s GWAS has been published (9). Although no single-nucleotide polymorphisms (SNPs)
met criteria for genome-wide significance (p<5×10−8), in aggregate, the top SNPs (p values <1×10−3) were
enriched for expression quantitative trait loci (eQTLs) in the frontal cortex and for methylation quantitative trait
loci (mQTLs) in the cerebellum, indicating that a significant proportion of these variants have biological
relevance to Tourette’s syndrome, and perhaps also to other tic disorders. However, as with other
neuropsychiatric disorders, much larger sample sizes are needed to elucidate the disorder’s genetic
underpinnings. Here, we report the results of a GWAS meta-analysis from the Psychiatric Genomics Consortium
(PGC) Tourette Syndrome Workgroup in a sample that is nearly four times larger than the initial GWAS (9). We
also probed aggregated Tourette’s syndrome polygenic risk to test two specific hypotheses: whether Tourette’s
and related tic disorders have an underlying shared genetic etiology and whether Tourette’s polygenic risk
scores correlate with worst-ever tic severity and may represent a future potential predictor of disease severity.

Methods
Study Subjects

The primary GWAS meta-analysis consisted of four European ancestry (EU) GWAS data sets: 1) 969 case subjects
and 3,923 ancestry-matched control subjects from the initial Tourette’s syndrome GWAS (GWAS1) (9); 2) 2,711
additional EU Tourette’s case subjects (4) and 3,762 ancestry-matched control subjects (GWAS2); 3) Tourette’s
probands from GWAS1 and one or more of their Tourette’s-affected family members (10) (N=548) plus 597
ancestry-matched control subjects (GWAS2 FAM); and 4) 591 independent EU Tourette’s probands from the

Tourette International Collaborative Genetics (TIC) study (11) and 1,206 unselected ancestry-matched control
subjects. Genotyping details are provided in Tables S1 and S2 in the online supplement.

GWAS1.

A total of 1,285 EU case subjects (number of cases from the GWAS1 paper) were collected from Tourette’s
syndrome specialty clinics in the United States, Canada, the United Kingdom, and the Netherlands or through
recruitment from the membership of the Tourette Association of America. Tourette’s diagnoses were based on
DSM-IV-TR criteria plus observation of tics by an experienced clinician. After removing the subjects who were
relatives or duplicates of subjects in GWAS2 or GWAS2 FAM, a total of 969 cases were retained for analysis. A
total of 3,923 control subjects were identified primarily from previously genotyped unselected population
control subjects and were ancestry-matched to the case subjects (9).

GWAS2.

A total of 2,871 EU case subjects with DSM-5 Tourette’s syndrome were identified by e-mail or online
recruitment combined with validated, web-based phenotypic assessments (12, 13) (N=1,264) or from Tourette’s
syndrome specialty clinics in the United States, Canada, and Europe (N=1,607) (see the Supplemental Methods
section in the online supplement). All subjects were genotyped at the UCLA Neuroscience Genomics Core. After
quality control, 2,711 case subjects were retained for analysis.

GWAS2 FAM.

The family sample consisted of 548 probands and first-degree relatives with Tourette’s syndrome from 207
independent families (10). A total of 175 probands came from the original Tourette’s GWAS1 sample; these case
subjects were removed from the GWAS1 analysis along with ancestry-matched control subjects and reanalyzed
with the family-based sample. Thirty-two Tourette’s probands and 341 additional Tourette’s-affected family
members (total N=373) were genotyped along with the GWAS2 case-control sample. A total of 597 ancestrymatched control subjects were selected from a pool of previously genotyped control subjects (see the
Supplemental Methods section in the online supplement).

TIC.

The TIC Genetics sample consisted of 591 probands, 579 of whom met DSM-5 criteria for Tourette’s syndrome
and 12 of whom met criteria for DSM-5 chronic motor or vocal tic disorder (see Tables S1 and S2 in the online
supplement).

Control subjects.

A total of 6,920 EU control subjects were obtained from cohorts of previously genotyped unselected population
control subjects for the GWAS2, GWAS2 FAM, and TIC Genetics analyses; an additional 595 EU control subjects
were genotyped with the Tourette’s case subjects at the UCLA Neuroscience Genomics Core (see Table S1 and
the Supplemental Methods section in the online supplement).

deCODE.

An independent case-control replication sample from Iceland (deCODE genetics, Reykjavik) consisted of 706
Icelandic Tourette’s syndrome case subjects and 466 case subjects with other tic disorders (chronic tics or
unspecified tic disorder) (see the Supplemental Methods section in the online supplement). A total of 127,164
unscreened population-matched control subjects were also available, of whom 6,068 were screened and
reported no lifetime subclinical motor or vocal tics. Case and control subjects were genotyped at deCODE on
Illumina SNP arrays (see the Supplemental Methods section).
Participants age 18 and older provided written informed consent; individuals under 18 gave assent, and parental
permission was obtained. The study was approved by the human subjects committees at all participating sites.

Quality Control

Genotyping quality control was performed in PLINK, version 1.9 (14) (see the Supplemental Methods section).
Duplicates and relatives were identified using genome-wide identity-by-descent estimates, and one member of
each duplicate or relative pair was removed from the case-control sample. Relative pairs in which both
individuals had a Tourette’s diagnosis were removed from the case-control sample and moved to the familybased analysis.
Population stratification was assessed through multidimensional scaling (MDS) analysis; individuals of nonEuropean ancestry and extreme outliers on each of the MDS components were removed (see the Supplemental
Methods section and Figure S1 in the online supplement). Case-control matching was verified across all MDS
components. The final post–quality control GWAS2 sample contained 2,711 case subjects, 3,762 ancestrymatched control subjects, and 550,550 SNPs; the final GWAS2 FAM sample contained 548 case subjects and
family members, 597 ancestry-matched control subjects, and 236,748 SNPs. The final TIC sample included 591
case subjects, 1,206 ancestry-matched control subjects, and 581,774 SNPs (see Table S2 in the online
supplement).

Imputation and Genome-Wide Association

SNP imputation was conducted on all genotype data for the primary meta-analyses using the 1000 Genomes
Project phase 1 integrated haplotypes (December 2013 release, with singleton sites removed) as the reference
panel (15). SHAPEIT was used to phase genotype data, followed by imputation with IMPUTE, version 2. SNPs
with INFO score <0.6 or certainty <0.9 were excluded.
Genome-wide association tests were performed on the imputed dosage data of the GWAS2 and TIC samples
separately in PLINK 1.9, using logistic regression under an additive model with the first four MDS components
and any additional MDS components associated with Tourette’s case-control status at p<0.05 included as
covariates. A linear mixed model was used for the GWAS2 FAM association analysis in MMM, version 1.0 (16), to
control for familial relatedness. GWAS1 samples were reimputed as described above; association tests were
performed in four ancestry-based strata: nonisolate European (GWAS1_EU), Ashkenazi Jewish (GWAS1_AJ),
French Canadian (GWAS1_FC), and GWAS1 TIC (GWAS1_TIC) (see Table S2).
A primary GWAS meta-analysis was conducted on the GWAS1, GWAS2, GWAS2 FAM, and TIC data sets using the
inverse-variance method in METAL (17). Heterogeneity was assessed with Cochran’s I2 statistic. The genomic
control factor (λ) was calculated for each individual GWAS and for the overall meta-analysis using all SNPs with
minor allele frequency (MAF) >0.01 to identify residual population stratification or systematic technical artifact
(see Figure S2 in the online supplement). GWAS summary statistics were subjected to linkage disequilibrium (LD)
score regression (LDSC) analyses on high-quality common SNPs (INFO score >0.9 and MAF >0.01) to examine the
LDSC intercept as a more specific measure of inflation of the GWAS test statistic (18) due to residual artifact or
stratification. The genome-wide significance threshold for the GWAS (19, 20) was set at a p value of 5.0×10−8.

Heritability Estimation

Tourette’s syndrome SNP-based heritability was estimated on the liability scale, assuming a population
prevalence of 0.8% (21), using both LDSC (18) and, in the GWAS1 and GWAS2 samples after excluding Ashkenazi
Jewish and French Canadian samples, genotype-level data in a linear mixed model framework (7). To compare
the relative polygenic burden of Tourette’s samples collected with different ascertainment methods, the
Tourette’s GWAS1 and GWAS2 data sets were separated into three groups: GWAS1 case subjects (25% from
affected sibling-pair families) (10); GWAS2 case subjects recruited through Tourette’s syndrome specialty clinics;
and GWAS2 case subjects recruited via e-mail from the membership of the Tourette Association of America and
assessed with a web-based phenotyping instrument (12). After additional stringent quality control of SNPs and

samples (see the Supplemental Methods section), the SNP-based heritability of each ascertainment group was
estimated both separately and jointly.
Partitioned heritability analyses were conducted using LDSC to evaluate enrichment of Tourette’s SNP-based
heritability from different functional annotation classes and different cell or tissue types (22) and to examine
genetic correlations between the GWAS1, GWAS2, and TIC data sets.

Targeted Replication

The population-based deCODE samples were used 1) to independently replicate the 39 top LD-independent
SNPs (r2<0.2 and MAF>0.01; p<1.0×10−5) in the primary meta-analysis, followed by a sign test to examine
consistency in the direction of effects in these top SNPs across the two data sets, as well as a targeted metaanalysis of these 39 SNPs using the inverse-variance method (see the Supplemental Methods section); and 2) to
examine the genetic relationships between Tourette’s and other tic disorders through polygenic risk score (PRS)
analyses (see the Supplemental Methods section) (23). Logistic regressions were performed to test the
prediction power of PRS for Tourette’s syndrome and tic disorder case subjects compared with control subjects,
adjusted by sex, year of birth, and the first 20 principal components (24).

Polygenic Risk Score Analyses

Genome-wide Tourette’s PRSs adjusted for ancestry principal components (aPRSs) were generated for all
subjects in the primary meta-analysis using the entire distribution (GWAS p≤1) of LD-independent SNPs (r2<0.2)
through a cross-validation approach (23) and used to examine the relationship between Tourette’s aPRS and
ascertainment, family history of Tourette’s or chronic tics, and lifetime worst-ever tic severity (Yale Global Tic
Severity Scale total tic score [tic severity], range 0–50) (see the Supplemental Methods section).

Gene-Based and Gene Set Enrichment Analysis

Gene-based tests and competitive gene set enrichment analyses were conducted in MAGMA (25) (see the
Supplemental Methods section). Gene-based test statistics were derived using association summary statistics for
all SNPs assigned to each gene including 50-kb flanking regions after accounting for LD, and p values were
adjusted with a Bonferroni correction for 18,079 genes genome-wide. Gene-based statistics were then analyzed
for tissue expression enrichment in 53 distinct human tissues from 714 donors using GTEx RNA-seq data (26),
and Bonferroni correction was applied for 53 tissue types (p=0.05/53=9.4×10−4). Tested gene sets included 107
probable autism spectrum disorder susceptibility genes from exome sequencing studies (27), evolutionarily
constrained genes (probability of loss-of-function intolerance score >0.9), previously identified constrained
genes harboring deleterious rare variants (large copy number variants or de novo loss-of-function mutations) in
Tourette’s case subjects (4, 5), and all Gene Ontology terms from the Molecular Signatures Database, version 6.0
(MSigDB 6.0) (see the Supplemental Methods section). Bonferroni correction was applied for the number of
gene sets tested.

Results
Genome-Wide Association Study

The final GWAS meta-analysis consisted of 8,265,319 SNPs in 4,819 Tourette’s syndrome case subjects and 9,488
control subjects. No evidence of residual population stratification or systematic technical artifact was observed
in any of the individual data sets (see Figure S2 in the online supplement) or in the final meta-analysis (λ=1.072,
λ1000=1.011) (Figure 1). LDSC indicated that 86% of the observed test statistic inflation was attributable to an
underlying genome-wide polygenic signal (see Figure S3 in the online supplement). PRS analyses in each
individual GWAS data set, derived using a leave-one-out approach, as well as in the deCODE sample, indicated
genetic homogeneity across all contributing data sets (see Figures S4 and S5 in the online supplement).

FIGURE 1. Results of the primary Tourette’s syndrome genome-wide association study meta-analysis of 4,819
case subjects and 9,488 control subjectsa
Panel A is a quantile-quantile plot of observed versus expected −log10(p) values from the primary genome-wide
association study (GWAS) meta-analysis. The 95% confidence interval of expected values is indicated in gray. The
genomic control λ value is 1.072, and the λ1000 value is 1.011 for single-nucleotide polymorphisms (SNPs) with
minor allele frequency >0.01, INFO score (measurement of imputation quality) >0.6, and certainty >0.9. Panel B
is a Manhattan plot of all final genotyped and imputed SNPs in the primary Tourette’s syndrome GWAS metaanalysis. The upper horizontal line indicates the genome-wide significance threshold of 5×10−8, and the lower
horizontal line indicates the suggestive threshold of 1.0×10−5.
a

The top SNP in the GWAS meta-analysis, rs2504235, located on chromosome 13q12.2, surpassed the genomewide significance threshold (odds ratio=1.16, p=2.1×10−8) (Table 1; see also Figure S6 in the online supplement).
rs2504235 lies within an intron of FLT3, encoding FMS-like tyrosine kinase 3. No other SNPs achieved genomewide significance, although rs1933437, a common FLT3 missense variant (Thr227Met) that lies 11.4 kb away
from and is in strong LD with rs2504235 (r2=0.93), had a p value of 8.2×10−8 (see Table S3 in the online
supplement). Across the genome, 39 LD-independent index SNPs with p values <1×10−5 were identified by LD
pruning (r2<0.2) followed by conditional association analyses controlling for the most significant SNP within each
2-Mb window and manual inspection of regional association plots to confirm the presence of supporting
statistical evidence of association from nearby SNPs (see Tables S3 and S4 in the online supplement). The top 10
LD-independent index SNPs are presented in Table 1.
TABLE 1. Top 10 linkage disequilibrium–independent loci in the primary Tourette’s syndrome GWAS metaanalysisa
Primary Meta-Analysis
SNP
CHR BP
A1/A2 INFO Score
rs2504235
13
28,612,886 A/G
0.99
rs191044310 10
23,705,451 A/T
0.83
rs13407215 2
161,544,891 T/C
1.00
rs2708146
2
58955953
G/A
1.009
rs1906252b
6
98,550,289 A/C
1.00
rs12459560 19
52,318,380 T/G
0.98
rs117648881 8
113,581,898 A/G
0.77
rs6670211
1
29,576,784 A/C
1.00
rs72853320 6
36,623,338 A/G
1.00

MAF
0.38
0.02
0.02
0.46
0.49
0.15
0.02
0.47
0.13

Odds Ratio
1.16
0.54
2.21
0.88
0.88
1.19
0.59
0.88
1.20

p
2.1E–08
1.5E–07
1.9E–07
3.2E–07
7.0E–07
8.2E–07
8.8E–07
1.4E–06
1.7E–06

rs73205493

0.34

1.16

1.8E–06

4

2,460,571

T/C

0.89

a For each linkage disequilibrium (LD) independent locus, the minor allele frequency (MAF), odds ratio, and association p
value of the index single-nucleotide polymorphism (SNP) is presented for the primary Tourette’s syndrome GWAS metaanalysis of 4,819 Tourette’s case subjects and 9,488 control subjects, for the targeted replication in the independent
deCODE sample (706 Tourette’s case subjects and 6,068 control subjects), and for the meta-analysis of these two data sets.

Complete annotation of these SNPs and all SNPs with association p values ,1.0310–5 is provided in Tables S3 and S4 in the
online supplement. CHR=chromosome; BP=hg19 position; A1=minor allele; A2=major allele; INFO score=measurement of
imputation quality; LD block=chromosomal regions where SNPs are in linkage disequilibrium with the index SNP (r2 .0.2)
with association p value,0.05. b rs1906252 and the LD block defined by r2.0.2 were reported to be associated with other
disorders and measures, including bipolar disorder, educational attainment, gut microbiota, and intelligence.

Targeted Replication

The 39 LD-independent index SNPs with p<1×10−5 were investigated for replication in the deCODE sample (706
case subjects, 6,068 control subjects). None of the individual SNPs were replicated after Bonferroni correction
(replication threshold for 39 tests, p<0.0013) (see Table 1; see also Table S4 in the online supplement); 23 of 39
putative Tourette’s syndrome risk alleles had the same direction of effect, although this was not statistically
significant (binomial two-way sign test, p=0.34).
Meta-analysis restricted to these 39 SNPs was conducted using summary statistics from the primary metaanalysis and the deCODE data with the inverse variance method in METAL. No SNP achieved genome-wide
significance; the SNP with the lowest p value was rs13407215, on chromosome 2 (p=1.9×10−7). rs2504235 was
not genome-wide significant in this analysis (p=2.4×10−7) (see Table 1; see also Table S4).

Heritability and PRS Analyses

Tourette’s syndrome SNP-based heritability (h2g) was estimated in the primary GWAS meta-analysis using LDSC
(h2g=0.21, SE=0.024, p<2.0×10−16). Pairwise genetic correlations across the three independent case-control data
sets (GWAS1, GWAS2, TIC) confirmed a significant shared polygenic architecture (GWAS1-GWAS2: rg=0.86,
SE=0.21, p=3.9×10−5; GWAS1-TIC: rg=0.84, SE=0.30, p=4.5×10−3; GWAS2-TIC: rg=0.93, SE=0.26, p=4×10−4).
Because the previous estimate of Tourette’s syndrome h2g from the first Tourette’s GWAS (linear mixed model,
h2g=0.58, SE=0.09) (7) was significantly higher than that observed in this study, additional heritability analyses
were conducted in the individual data sets, stratified on ascertainment status, using linear mixed models (LMM)
(7) (Table 2). These analyses confirmed both the high SNP-based heritability of the sibling-pair-enriched
Tourette’s GWAS1 sample (GWAS1-LMM: h2g=0.56, SE=0.10; p=1.2×10−9) and the lower heritability of the larger
GWAS2 sample (GWAS2-LMM: h2g=0.29, SE=0.04; p=5.5×10−14).
TABLE 2. Single-nucleotide polymorphism–based heritability estimates derived using a linear
mixed model method for the Tourette’s syndrome GWAS1 and GWAS2 European ancestry case-control samplesa
Case Subjects
Control Subjects
Sample
N
% N
% V(G)/Vp_Lb SE
p
GWAS1
559
14 3,400
86 0.565
0.096 1.2310–9
c
GWAS2
2,146
46 2,564
54 0.288
0.040 5.5310–14
GWAS2c web-based 934
27 2,564
73 0.294
0.067 2.4310–6
c
GWAS2 clinic-based 1,098
30 2,564
70 0.284
0.059 4.0310–7

a Heritability estimates were calculated first for the entire Tourette’s syndrome GWAS1 and GWAS2 samples; subsequently,
the Tourette’s GWAS2 sample was separated into two subsets based on case ascertainment method (clinic-based versus
web-based). The TIC Genetics case-control sample was not large enough to obtain an independent heritability estimate
using a linear mixedmodel approach. All heritability estimates are presented on the liability scale. Subjects from European
population isolates (Ashkenazi Jewish and French Canadian)were excluded from the linear mixed-model analyses.
b Tourette’s syndrome prevalence was defined as 0.8%.
c GWAS2 family data were not included in the heritability estimate.

To explore the hypothesis that the lower heritability of the Tourette’s GWAS2 sample may have arisen from the
inclusion of Tourette’s case subjects diagnosed in the community and ascertained using a validated web-based
screen (12, 13), the GWAS2 case-control sample was divided into clinic-based and web-based case subjects, and

the LMM-based heritability analyses were repeated. Contrary to the predicted hypothesis, both subsets had the
same heritability (GWAS2-clinic: h2g=0.29, SE=0.07; p=1.2×10−9; GWAS2-web: h2g=0.28, SE=0.10; p=1.2×10−9)
(see Table 2).

Tourette’s Syndrome PRS in Multiplex Versus Simplex Families

Since a large proportion of Tourette’s GWAS1 case subjects were derived from affected sibling-pair families,
which might be expected to harbor higher Tourette’s syndrome polygenic risk than case subjects from simplex
families without affected first-degree relatives, we examined the relationship between ancestry-adjusted PRS
(aPRS) in case subjects from multiplex families (positive for first-degree relative family history) compared with
simplex families (negative for first-degree relative family history) (see the Supplemental Methods section).
Because multiplex Tourette’s syndrome case subjects with a Tourette’s-affected parent or sibling (N=417)
demonstrated mean aPRSs similar to Tourette’s GWAS case subjects with a chronic tic-affected parent or sibling
(N=111) (F=0.12, df=1, p=0.73), we combined both Tourette’s case groups for further analyses
(Tourette’s/chronic tic family history positive case subjects, N=528). The combined Tourette’s/chronic tic
multiplex case subjects had a significantly higher mean aPRS compared with the aPRS from Tourette’s/chronic
tic simplex case subjects (N=346) (F=4.90, df=1, p=0.027), confirming that multiplex case subjects were enriched
for Tourette’s polygenic risk (see Figure S7 in the online supplement).

Tourette’s Syndrome PRS and Tic Severity

Given the strong enrichment of Tourette’s aPRS in case subjects from multiplex families, Tourette’s/chronic tic
family history positive Tourette’s case subjects were examined next to test whether Tourette’s aPRS may serve
as a predictor of higher disease severity in these case subjects (see the Supplemental Methods section). After
adjustment for residual population stratification using the first four principal components, higher Tourette’s
aPRS was significantly correlated with increased worst-ever tic severity (β=0.93, SE=0.42, p=0.026), with every
one-standard-deviation increase in Tourette’s aPRS corresponding to a 0.93-point increase in worst-ever tic
severity (total range, 0–50).

Tourette’s Syndrome and Tic Spectrum Phenotypes

Given the hypothesis that Tourette’s and other tic disorders represent a phenotypic spectrum with a shared
genetic etiology, Tourette’s PRS derived from the GWAS meta-analysis was compared in Tourette’s and tic
spectrum case subjects in the Icelandic deCODE sample (Figure 2; see also Figure S5 in the online supplement).
Tourette’s PRS was significantly higher in both deCODE Tourette’s case subjects and tic spectrum case subjects
compared with control subjects (odds ratio=1.33, p=5.3×10−9, and odds ratio=1.20, p=5.2×10−4, respectively),
explaining 0.78% and 0.42% of the phenotypic variance, respectively. Direct comparison between case groups
confirmed that deCODE Tourette’s case subjects carried a higher Tourette’s syndrome polygenic burden than
subjects with other tic spectrum disorders (odds ratio=1.14, p=0.05), representing an excess 0.37% of the
phenotypic variance (see Figure 2).

FIGURE 2. Density plot demonstrating the distribution of Tourette’s syndrome polygenic risk scores (PRSs) in
population-based Icelandic Tourette’s case subjects, tic disorder case subjects, unscreened population control
subjects, and tic-negative control subjectsa
The x-axis represents the scaled Tourette’s syndrome PRS score, where an increase of one standard deviation
in PRS score doubles Tourette’s syndrome risk. The dashed lines correspond to the mean of the respective
groups. The black dotted line toward the right corresponds to one standard deviation from the population
mean.
a

Enrichment of Tourette’s Syndrome Heritability by Functional Annotation and Gene
Expression

Tourette’s syndrome SNP-based heritability (h2g) from the GWAS meta-analysis was also used as a genome-wide
probe to test whether aggregated Tourette’s syndrome genetic risk may be concentrated either in 52 specific
functional genomic elements (e.g., promoters, enhancers, epigenetic marks) or in gene expression patterns from
10 grouped tissue or cell types using partitioned LDSC (22). Evolutionarily conserved SNPs (2.6% of all SNPs)
were enriched 16.5-fold for Tourette’s h2g, accounting for 42.3% of Tourette’s syndrome heritability
(Pr[h2g]/Pr[SNPs]=16.5, SE=5.3, p=3.6×10−3, not significant after correction). A parallel analysis including these
evolutionarily conserved SNPs plus 500-bp flanking windows (33% of all SNPs) was enriched 2.8-fold for
Tourette’s h2g and accounted for 92.4% of Tourette’s syndrome heritability (Pr[h2g]/Pr[SNPs]=2.80, SE=0.46,
p=1.0×10−4; p=0.005 after correction) (see Figure S8 in the online supplement). No other genomic annotations
were significantly enriched for Tourette’s SNP-based heritability. In the cell-type analysis, significant enrichment
was found only for CNS cell types, with 62.7% of Tourette’s syndrome heritability contributed by 14.8% of SNPs
(p=4.2×10−8; p=4.2×10−7 after correction) (see Figure S9 in the online supplement).

Gene-Based Association and Enrichment Analyses

Gene-based association and enrichment tests were performed using meta-analysis summary statistics in
MAGMA and gene expression data in GTEx (https://www.gtexportal.org/home/). FLT3 was identified with
genome-wide significant association after correcting for 18,079 gene tests (p=8.9×10−7) (see Figure S10 in
the online supplement). The most significant SNP in the FLT3 locus, rs2504235, was the only SNP surpassing
genome-wide significance threshold in the primary meta-analysis and was significantly associated
with FLT3 expression level both in cerebellum (p=6.5×10−10) and cerebral cortex (p=2.6×10−11). No gene set was
significantly associated with Tourette’s syndrome after Bonferroni correction. In the gene expression
enrichment analyses of 53 adult human tissues, only dorsolateral prefrontal cortex (Brodmann’s area 9)
demonstrated significant enrichment of Tourette’s-associated genes after correction (β=0.023, SE=0.0069,
p=1.2×10−4) (Figure 3; see also the Supplemental Methods section).

FIGURE 3. Gene expression enrichment analysis of genome-wide Tourette’s syndrome polygenic risk in 53 adult
human tissuesa
Gene-based test statistics were derived from Tourette’s syndrome GWAS meta-analysis summary statistics on
single-nucleotide polymorphisms (SNPs) with minor allele frequency >0.01 and INFO score (measurement of
imputation quality) >0.9. SNPs were assigned to genes based on their position according to NCBI Build 37.3 and
50-kb upstream and downstream flanking regions. Summary statistics on 18,079 genes were generated. The
European panel of the 1000 Genomes data (phase 3) was used as the reference panel to account for linkage
disequilibrium. GTEx (version 7) RNA-seq data expression values were log2 transformed with a pseudo-count of
1 after Winsorization at 50, and the average was taken per tissue. Fifty-three specific tissue types were tested
separately in MAGMA (23). The significance threshold for the tissue-specific test was calculated using the
Bonferroni method (alpha=0.05/53, p<9.43×10−4). Frontal cortex (Brodmann’s area [BA] 9), corresponding to
dorsolateral prefrontal cortex, demonstrated significant enrichment of Tourette’s-related genes after correction
for multiple hypothesis testing.
a

Discussion
Tourette’s syndrome has long been conceptualized as part of a spectrum of developmental tic disorders, with
transient tics at one end (1) and severe Tourette’s syndrome with multiple psychiatric comorbidities at the
other. However, until recently, potential biological relationships between the various tic disorders were
unknown, as were the underlying genetic contributions to tic severity. The results of this study further illuminate
the genetic architecture of Tourette’s syndrome and its relationships to phenotypic expression. First, the PRS
analyses probing the genetic architecture of tic disorders in the population-based Icelandic sample demonstrate
that individuals with Tourette’s syndrome share the same underlying polygenic risk as those with other tic
disorders. Furthermore, the observation that Tourette’s syndrome case subjects have a significantly higher
mean PRS than those with non-Tourette’s tic disorders provides evidence for a liability spectrum of genetic risk
within tic disorders. Lastly, within Tourette’s syndrome case subjects, the finding that higher Tourette’s PRS was

associated with greater tic severity also builds on our previous analyses demonstrating a relationship between
higher Tourette’s PRS and the presence of complex symmetry and socially inappropriate tics (28). These
relationships, although hypothesized on the basis of clinical observations, have not previously been
demonstrated at the molecular genetic level, and ultimately they will help provide insight into the molecular
mechanisms of tic development and expression.
These observations have direct biological and clinical relevance. First, they support previous efforts to
conceptualize Tourette’s and chronic tics as a unified condition and to combine them into a single tic spectrum
disorder in future diagnostic schemas (1). Although traditionally separated clinically into distinct disorders,
chronic/persistent tic disorders, whether consisting of motor tics, vocal tics, or both, appear to be due to the
same underlying genetic causes. Second, while the small proportion of explained variance in worst-ever tic
severity is a limitation of the present study, work in other polygenic psychiatric disorders, such as schizophrenia,
has repeatedly demonstrated that as GWAS sample sizes increase, the proportion of phenotype explained by
polygenic risk scores increases markedly (29). It is therefore possible that in the future, Tourette’s PRS may be a
potential candidate for predicting both conversion to chronic tics in the 20%−25% of children who present with
transient tics (1) and, at the other end of the phenotypic spectrum, tic persistence and lifetime tic severity in
those with Tourette’s syndrome. Finally, particularly important in the context of the very large sample sizes
required for the success of GWAS efforts, our results suggest that future genetic association studies may benefit
from expanding disease definitions to include case subjects with both Tourette’s and chronic tics.
Our genome-wide cell and tissue-based enrichment analyses implicate modulation of gene expression through
noncoding variants as a fundamental mechanism in the pathogenesis of Tourette’s syndrome. All of the top
tissues in the enrichment analyses were derived from brain, although dorsolateral prefrontal cortex
(Brodmann’s area 9) was the only tissue in which eQTL enrichment surpassed Bonferroni correction. The five
tissues with the strongest eQTL enrichment (frontal cortex, caudate, putamen, nucleus accumbens, and
cerebellum) all represent key nodes within the cortico-striatal and cortico-cerebellar circuits that have been
implicated in Tourette’s pathophysiology (1). These results support the hypothesis that Tourette’s syndrome is a
developmental circuit disorder affecting motor, cognitive, and behavioral control (as manifested by tics and
attention-deficit and obsessive-compulsive symptoms) and suggest that future GWAS analyses in larger data
sets should aid in identifying not only the individual genes underlying susceptibility to Tourette’s syndrome but
also core pathways in the development and regulation of these circuits that could serve as targets for
modulation-based therapies.

Limitations

This study has several potential limitations, the most significant of which is the sample size. Although this is the
largest Tourette’s syndrome GWAS conducted to date, our sample of fewer than 5,000 case subjects is clearly
not yet sufficient to identify definitive Tourette’s susceptibility variants, as demonstrated by the failure of the
top GWAS SNP to replicate in the deCODE sample. Additional potential limitations are also related to sample
size, including reduced power to examine additional clinical variables of interest, such as age at onset of tics and
co-occurring psychiatric illnesses such as obsessive-compulsive disorder and attention deficit hyperactivity
disorder. However, we anticipate that most, if not all, of these limitations can be resolved by substantial
increases in the number of Tourette’s syndrome case subjects collected for GWAS, an effort that is currently
under way.
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